AWH ANNOUNCES FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
- Impressive net revenue growth of 25% and 28% year-over-year for Q4 2023 and full year 2023 respectively.
- Adjusted EBITDA increased by 15% and 14% year-over-year for Q4 and full year 2023.
- First full year of positive cash from operations and positive free cash flow.
- Ended Q4 2023 with $73 million in cash and cash equivalents.
- Opened six dispensaries in 2023 and launched the 'Cannabis Outlet Model' in select markets.
- Appointed new leadership team members during the year.
- Net loss increased in Q4 2023 compared to Q4 2022.
- Net loss for full year 2023 was higher than in FY 2022.
- Adjusted EBITDA margin decreased compared to the prior year.
- Net debt was relatively high at $236.2 million as of December 31, 2023.
Q4 2023 Net Revenue Increased
Q4 2023 Adjusted EBITDA Increased
Full Year 2023 Net Revenue Increased
Full Year 2023 Adjusted EBITDA Increased
First Full Year of Positive Cash from Operations and Positive Free Cash Flow
Company Ended Q4 2023 with
Financial Highlights
- Gross Revenue:
- Q4 2023: Total revenue of
increased$173.1 million 1.9% quarter-over-quarter and increased28.7% year-over-year. - FY 2023: Total revenue of
increased$635.2 million 30.3% year-over-year.
- Q4 2023: Total revenue of
- Net Revenue:
- Q4 2023: Net revenue, which excludes intercompany sale of wholesale products, decreased
0.8% quarter-over-quarter to , and increased$140.2 million 25.0% year-over year. - FY 2023: Net revenue increased
27.8% year-over year to .$518.6 million
- Q4 2023: Net revenue, which excludes intercompany sale of wholesale products, decreased
- Net Loss:
- Q4 2023: Net loss of
compared to net loss of$19.3 million in Q4 2022.$15.1 million - FY 2023: Net loss of
compared to net loss of$48.2 million for FY 2022.$80.9 million
- Q4 2023: Net loss of
- Adjusted EBITDA1:
- Q4 2023: Adjusted EBITDA was
, a$32.4 million 9.6% increase quarter-over-quarter and a14.8% increase year-over-year. Adjusted EBITDA Margin was23.1% , a 218 basis point increase compared to the prior quarter and a 207 basis point decrease compared to the prior year. - FY 2023: Adjusted EBITDA was
, a$106.5 million 14.3% increase year-over-year. Adjusted EBITDA Margin was20.5% , a 243 basis point decrease compared to the prior year.
- Q4 2023: Adjusted EBITDA was
- Balance Sheet:
- As of December 31, 2023, cash and cash equivalents were
, and net debt2, which equals total debt less unamortized deferred financing costs less cash and cash equivalents, was$72.5 million .$236.2 million
- As of December 31, 2023, cash and cash equivalents were
- Cash Flow:
- Q4 2023: Generated
Cash from Operations in the quarter, representing the fourth quarter in a row the Company generated Cash from Operations. Generated$16.7 million Free Cash Flow3 in the quarter, representing the second quarter in a row the Company generated positive Free Cash Flow.$8.4 million - FY 2023: Generated
Cash from Operation3 in the full year, representing the first full year the Company generated Cash from Operations since the Company was founded. Generated$54.5 million Free Cash Flow3 for the full year, representing the first full year the Company generated generated positive Free Cash Flow. Both of these metrics exclude the benefit of$30.3 million in cash that the Company received throughout the year attributable to an Employee Retention Tax Credit.$20.8 million
- Q4 2023: Generated
Full Year 2023 Business Highlights
- First full year generating positive Cash from Operations and Positive Free Cash Flow.
- Opened six dispensaries during 2023, made up of
Grand Rapids, MI ;New Bedford, MA ;Tinley Park, IL ;Piqua, OH ;Sandusky, OH ; andNorthlake, IL. Subsequent to year-end, the Company opened a dispensary inCincinnati, OH , bringing the total to 35 dispensaries. - During the year, the Company was the first multi-state operator in
the United States to launch the 'Cannabis Outlet Model' in select markets. AWH outlets feature the same great products at everyday low prices. The Company has deployed this model in eight of its dispensaries. - In April, the Company acquired four dispensaries in
Maryland , marking the Company's entry into its seventh state. Soon after the purchase, the Company began adult-use inMaryland at the start of the program in July. - Sold more than 165,000 pounds of product wholesale, more than doubling pounds sold compared to prior-year. Full year gross wholesale revenue increased in all six wholesale markets compared to prior year.
- Simply Herb brand rose to the number one selling brand in
Massachusetts . Ozone rose to number three selling brand inNew Jersey and remained number three selling brand inIllinois . Overall, AWH brands were number four in all of the third-party wholesale markets in which the Company competes. - Launched three new brands in the year, Royale, a super premium brand; Tunnel Vision, a brand high in Tetrahydrocannabivarin (THCV); and Common Goods, a value-based flower brand.
- In May, the Company appointed John Hartmann as Chief Executive Officer of the Company. Later in the year, the Company announced key leadership changes. These changes included the appointment of Mark Cassebaum as Chief Financial Officer; the appointment of Chris Holzer as Chief of Operations; the appointment of Rick Wilkins as Chief of Stores; and the appointment of Denise Pedulla as Chief Legal Officer and Corporate Secretary. Subsequent to the end of the year, Melissa Feck was appointed Chief People Officer.
___________________________________ | |
1 | Please see the "Supplemental Information (Unaudited) Regarding Non-GAAP Financial Measures" at the end of this press release for a reconciliation of non-GAAP to GAAP measures. |
2 | Net Debt is defined as Total debt less cash and cash equivalents less unamortized deferred financing costs. |
3 | Free Cash Flow is defined as Cash from Operations less net Additions to Capital Assets. Cash from Operations and Free Cash Flow for the full year exclude exclude the benefit of |
Management Commentary
Abner Kurtin, Executive Chairman of AWH said, "Thank you to our stakeholders for helping us deliver a strong Q4 and full year 2023. We remain excited about our future prospects, as we continue to anticipate positive changes in federal cannabis reform. Further to the federal progress, we are seeing promising advancements across the states. We were pleased
John Hartmann, Chief Executive Officer added, "AWH had an excellent quarter and full year. Our notable achievements translated into impressive financial success, with 2023 net revenue reaching
Mark Cassebaum, Chief Financial Officer stated, "We are pleased to have generated meaningful cash from operations and free cash flow for the quarter and for the full-year. This is particularly important as we are in the early stages of discussions to refinance our term loan due in August 2025. These conversations have been productive, and we are pleased with the initial reception in the market. We remain committed to disciplined growth, and investing in low-risk capex opportunities that present a high return on invested capital."
Q4 2023 Financial Overview
Net revenue, which excludes intercompany sales of wholesale products, decreased
Total retail revenue decreased
Gross wholesale revenue in the quarter was
Q4 2023 gross profit was
Q4 2023 Adjusted Gross Profit1 was
Adjusted Gross Profit1 margin on a consolidated-basis increased 294 basis points quarter-over-quarter to
Total general and administrative ("G&A") expenses for Q4 2023 were
Net loss attributable to AWH for Q4 2023 was
Adjusted EBITDA1, which adjusts for tax, interest, depreciation, amortization, equity-based compensation, and other items deemed one-time in nature, was
Full Year 2023 Financial Overview
Net revenue, which excludes intercompany sale of wholesale products, increased
Total retail revenue was
For the full year 2023, the Company expanded gross wholesale by
Full year 2023 gross profit was
Full year 2023 Adjusted Gross Profit1 was
Total G&A expenses for 2023 were
Net loss for 2023 was
Adjusted EBITDA1, was
Non-GAAP Financial Information
This press release includes certain non-GAAP financial measures as defined by the
Conference Call and Webcast
AWH will host a conference call on March 12, 2024 at 8:30 a.m. ET to discuss its financial results for the quarter and year ended December 31, 2023. The conference call may be accessed by dialing (888) 390-0605. A live audio webcast of the call will also be available on the Investor Relations section of AWH's website at https://awholdings.com/investors/.
About Ascend Wellness Holdings, Inc.
AWH is a vertically integrated multi-state cannabis operator with licenses and assets in
Additional information relating to the Company's fourth quarter and full year 2023 results is available on the Investor Relations section of AWH's website at https://awholdings.com/investors/, the SEC's Electronic Data Gathering, Analysis and Retrieval System ("EDGAR") at www.sec.gov and
Cautionary Note Regarding Forward-Looking Information
This news release includes forward-looking information and statements (together, "forward-looking statements"), which may include, but are not limited to, the plans, intentions, expectations, estimates, and beliefs of the Company. Words such as "expects", "continue", "will", "anticipates" and "intends" or similar expressions are intended to identify forward-looking statements. Without limiting the generality of the preceding statement, all statements in this press release relating to estimated and projected revenue, expectations regarding production capacity, anticipated capital expenditures, expansion, profit, product demand, margins, costs, cash flows, sources of capital, growth rates, potential acquisitions, closing dates for transactions, regulatory approvals, future facility openings, and future financial and operating results.
We caution investors that any such forward-looking statements are based on the Company's current projections and expectations about future events and financial trends, the receipt of all required regulatory approvals, and on certain assumptions and analysis made by the Company in light of the experience of the Company and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate.
Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein. Such factors include, among other, the risks and uncertainties identified in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and in the Company's other reports and filings with the applicable Canadian securities administrators on its profile on SEDAR+ at www.sedarplus.ca and the SEC on its profile on EDGAR at www.sec.gov. Although the Company believes that any forward-looking statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such statements, there can be no assurance that any such forward-looking statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information. Any forward-looking statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward-looking statements herein, whether as a result of new statements, future events or results, or otherwise, except as required by applicable laws. No securities regulator nor the Canadian Securities Exchange has reviewed, approved or disapproved the content of this press release.
Pre-Released Financial Metrics
This press release contains certain pre-released fourth quarter and full year financial metrics. The fourth quarter and full year financial metrics contained in this press release are preliminary and represent the most current information available to the Company's management, as financial closing procedures for the three months and year ended December 31, 2023 are not yet complete. The Company's actual consolidated audited financial statements for such period will be filed with the applicable Canadian securities administrators on its profile on SEDAR at https://www.sedarplus.ca/and the SEC on its profile on EDGAR at www.sec.gov, and may result in material changes to the financial metrics summarized in this press release (including by any one financial metric, or all of the financial metrics, being below or above the figures indicated) as a result of the completion of normal quarter and year-end accounting procedures and adjustments, and also what one might expect to be in the final consolidated financial statements based on the financial metrics summarized in this press release. Although the Company believes the expectations reflected in this press release are based upon reasonable assumptions, the Company can give no assurance that actual results will not differ materially from these expectations.
Three Months Ended | Year Ended | ||||||
(in thousands, except per share amounts) | 2023 | 2022 | 2023 | 2022 | |||
Revenue, net | $ 140,158 | $ 112,099 | $ 518,590 | $ 405,926 | |||
Cost of goods sold | (92,617) | (70,587) | (363,470) | (271,363) | |||
Gross profit | 47,541 | 41,512 | 155,120 | 134,563 | |||
Operating expenses | |||||||
General and administrative expenses | 46,977 | 36,130 | 158,739 | 137,089 | |||
Settlement expense | — | — | — | 5,000 | |||
Total operating expenses | 46,977 | 36,130 | 158,739 | 142,089 | |||
Operating profit (loss) | 564 | 5,382 | (3,619) | (7,526) | |||
Other (expense) income | |||||||
Interest expense | (8,565) | (8,725) | (36,984) | (32,436) | |||
Other, net | 632 | 229 | 25,843 | 756 | |||
Total other expense | (7,933) | (8,496) | (11,141) | (31,680) | |||
Loss before income taxes | (7,369) | (3,114) | (14,760) | (39,206) | |||
Income tax expense | (11,974) | (11,936) | (33,454) | (41,693) | |||
Net loss | $ (19,343) | $ (15,050) | $ (48,214) | $ (80,899) | |||
Net loss per share attributable to Class A and Class B stockholders of Ascend Wellness Holdings, Inc. — basic and diluted | $ (0.09) | $ (0.08) | $ (0.24) | $ (0.44) | |||
Weighted-average common shares outstanding — basic and diluted | 206,611 | 188,026 | 199,154 | 183,381 |
Three Months Ended | Year Ended | ||||||
(in thousands) | 2023 | 2022 | 2023 | 2022 | |||
Net cash provided by (used in) operating activities | $ 16,668 | $ (16,071) | $ 75,334 | $ (38,356) | |||
Cash flows from investing activities | |||||||
Additions to capital assets | (8,236) | (18,683) | (24,248) | (81,642) | |||
Investments in notes receivable | — | (381) | (15,169) | (2,772) | |||
Collection of notes receivable | 82 | 82 | 327 | 327 | |||
Proceeds from sale of assets | — | — | 15,000 | 39,225 | |||
Acquisition of businesses, net of cash acquired | — | (250) | (19,857) | (25,140) | |||
Purchases of intangible assets | — | (471) | (15,943) | (44,252) | |||
Net cash used in investing activities | (8,154) | (19,703) | (59,890) | (114,254) | |||
Cash flows from financing activities | |||||||
Proceeds from issuance of common stock in private placement | — | — | 7,000 | — | |||
Proceeds from issuance of debt | — | 19,364 | — | 84,364 | |||
Repayments of debt | — | (854) | (23,188) | (3,143) | |||
Proceeds from finance leases | — | 350 | — | 350 | |||
Repayments under finance leases | (113) | (46) | (369) | (69) | |||
Debt issuance costs | — | — | — | (4,998) | |||
Proceeds from exercise of stock options | 186 | — | 186 | — | |||
Taxes withheld under equity-based compensation plans, net | — | (287) | (711) | (5,229) | |||
Net cash provided by (used in) financing activities | 73 | 18,527 | (17,082) | 71,275 | |||
Net increase (decrease) in cash, cash equivalents, and restricted cash | 8,587 | (17,247) | (1,638) | (81,335) | |||
Cash, cash equivalents, and restricted cash at beginning of period | 63,921 | 91,393 | 74,146 | 155,481 | |||
Cash, cash equivalents, and restricted cash at end of period | $ 72,508 | $ 74,146 | $ 72,508 | $ 74,146 |
December 31, | |||
(in thousands) | 2023 | 2022 | |
Cash and cash equivalents | $ 72,508 | $ 74,146 | |
Inventory | 95,294 | 97,532 | |
Other current assets | 61,058 | 27,065 | |
Property and equipment, net | 268,082 | 279,860 | |
Operating lease right-of-use assets | 130,556 | 108,810 | |
Intangible assets, net | 221,452 | 221,093 | |
Goodwill | 47,538 | 44,370 | |
Other noncurrent assets | 23,062 | 19,284 | |
Total Assets | $ 919,550 | $ 872,160 | |
Total current liabilities | $ 92,686 | $ 110,949 | |
Long-term debt, net | 297,565 | 319,297 | |
Operating lease liabilities, noncurrent | 261,087 | 229,816 | |
Other non-current liabilities | 125,340 | 48,683 | |
Total stockholders' equity | 142,872 | 163,415 | |
Total Liabilities and Stockholders' Equity | $ 919,550 | $ 872,160 |
We define "Adjusted Gross Profit" as gross profit excluding non-cash inventory costs, which include depreciation and amortization included in cost of goods sold, equity-based compensation included in cost of goods sold, start-up costs included in cost of goods sold, and other non-cash inventory adjustments. We define "Adjusted Gross Margin" as Adjusted Gross Profit as a percentage of net revenue. Our "Adjusted EBITDA" is a non-GAAP measure used by management that is not defined by GAAP and may not be comparable to similar measures presented by other companies. We define "Adjusted EBITDA Margin" as Adjusted EBITDA as a percentage of net revenue. Management calculates Adjusted EBITDA as the reported net loss, adjusted to exclude: income tax expense, other (income) expense, interest expense, depreciation and amortization, depreciation and amortization included in cost of goods sold, non-cash inventory adjustments, equity-based compensation, equity-based compensation included in cost of goods sold, start-up costs, start-up costs included in cost of goods sold, transaction-related and other non-recurring expenses, litigation settlement, and gain or loss on sale of assets. Accordingly, management believes that Adjusted EBITDA provides meaningful and useful financial information, as this measure demonstrates the operating performance of the business. Non-GAAP financial measures may be considered in addition to the results prepared in accordance with GAAP, but they should not be considered a substitute for, or superior to, GAAP results. The Company's presentation of these financial measures may not be comparable to similar non-GAAP measures used by other companies. These financial measures are intended to provide additional information to investors concerning the Company's performance.
The following table presents Adjusted Gross Profit for the fourth quarter and year ended December 31, 2023 and 2022:
Three Months Ended | Year Ended | |||||||
($ in thousands) | 2023 | 2022 | 2023 | 2022 | ||||
Gross Profit | $ 47,541 | $ 41,512 | $ 155,120 | $ 134,563 | ||||
Depreciation and amortization included in cost of goods sold | 7,184 | 3,742 | 29,449 | 15,360 | ||||
Equity-based compensation included in cost of goods sold | 2,054 | 1,836 | 6,511 | 11,627 | ||||
Start-up costs included in cost of goods sold(1) | — | 2,263 | 1,570 | 13,044 | ||||
Non-cash inventory adjustments(2) | 3,298 | 4,113 | 16,350 | 10,478 | ||||
Adjusted Gross Profit | $ 60,077 | $ 53,466 | $ 209,000 | $ 185,072 | ||||
Adjusted Gross Margin | 42.9 % | 47.7 % | 40.3 % | 45.6 % |
(1) | Incremental expenses associated with the expansion of activities at our cultivation facilities that are not yet operating at scale, including excess overhead expenses resulting in delays from regulatory approvals at certain cultivation facilities. |
(2) | Consists of write-offs of expired products, obsolete packaging, and net realizable value adjustments related to certain inventory items. |
The following table presents Adjusted EBITDA for the fourth quarter and year ended December 31, 2023 and 2022:
Three Months Ended December 31, | Year Ended December 31, | |||||||
($ in thousands) | 2023 | 2022 | 2023 | 2022 | ||||
Net loss | $ (19,343) | $ (15,050) | $ (48,214) | $ (80,899) | ||||
Income tax expense | 11,974 | 11,936 | 33,454 | 41,693 | ||||
Other income, net | (632) | (229) | (25,843) | (756) | ||||
Interest expense | 8,565 | 8,725 | 36,984 | 32,436 | ||||
Depreciation and amortization | 14,791 | 8,776 | 58,983 | 29,455 | ||||
Non-cash inventory adjustments(1) | 3,298 | 4,113 | 16,350 | 10,478 | ||||
Equity-based compensation | 5,600 | 3,059 | 18,344 | 22,995 | ||||
Start-up costs(2) | 579 | 6,669 | 3,888 | 23,356 | ||||
Transaction-related and other non-recurring expenses(3) | 7,519 | 297 | 12,788 | 9,119 | ||||
(Gain) loss on sale of assets | — | (105) | (226) | 345 | ||||
Litigation settlement | — | — | — | 5,000 | ||||
Adjusted EBITDA | $ 32,351 | $ 28,191 | $ 106,508 | $ 93,222 | ||||
Adjusted EBITDA Margin | 23.1 % | 25.1 % | 20.5 % | 23.0 % |
(1) | Consists of write-offs of expired products, obsolete packaging, and net realizable value adjustments related to certain inventory items. |
(2) | One-time costs associated with acquiring real estate, obtaining licenses and permits, and other costs incurred before commencement of operations at certain locations, as well as incremental expenses associated with the expansion of activities at our cultivation facilities that are not yet operating at scale, including excess overhead expenses resulting in delays from regulatory approvals at certain cultivation facilities. The year ended December 31, 2022 includes a |
(3) | Legal and professional fees associated with litigation matters, potential acquisitions, and other regulatory matters and other non-recurring expenses, including fair value adjustments related to an earn-out and certain reserves. The 2023 amounts also include severance-related expenses and certain contract termination payments. |
View original content:https://www.prnewswire.com/news-releases/awh-announces-fourth-quarter-and-full-year-2023-financial-results-302085980.html
SOURCE Ascend Wellness Holdings, Inc.
FAQ
What was the percentage increase in net revenue for Q4 2023?
How did Adjusted EBITDA perform for full year 2023?
What was the company's cash and cash equivalents at the end of Q4 2023?
How many dispensaries did the company open in 2023?
What new brands did the company launch in the year?